Mavenclad® for Multiple Sclerosis

How many people get multiple sclerosis a year in the United States?

Nearly 4,300 people were diagnosed with MS in 2017. It is estimated that about 100,000 new cases of MS will be registered with the CDC in year 2020.

What is multiple sclerosis?

Despite the fact that several of the symptoms of MS are quite common in other diseases, we believe that MS presents a unique diagnostic challenge because it is an illness in which all symptoms are present in an atypical manner. Although in practice there is a tremendous diagnostic and therapeutic opportunity as the number of patients diagnosed with MS increases, clinicians cannot know at presentation what the most appropriate disease diagnosis is. Therefore, we have developed a diagnostic diagnostic triad of MS using well established diagnostic techniques that will allow prompt and efficient differentiation between the most commonly occurring MS-like syndromes.

What are the signs of multiple sclerosis?

In MS patients, the clinical course of the condition is variable. This variability is mainly explained by the presence or absence of lesions. The most frequent signs of MS are fatigue, dyspnoea, tremor, spasticity, and loss of sensation (loss of the tingling sensation). Most of these signs tend to occur concomitantly. Anosmia is also a common feature and is present in about 50–75% of MS patients at different stages of the disease.

What causes multiple sclerosis?

There is no single cause for MS; thus, current hypotheses need to be revised. It is not clear if both genes and environmental factors play a significant role in the development of MS. The role of genetic and environmental factors varies by ethnic group and in different areas within the global population.

Can multiple sclerosis be cured?

Although multiple sclerosis can be highly disabling, it is easily and completely curable with medication or immunomodulatory therapies. However, this does not mean that the disease cannot cause any permanent damage to the nervous system or that it is an incurable disease.

What are common treatments for multiple sclerosis?

In MS, the first line of treatment is typically with nonsteroidal anti-inflammatory drugs, such as ibuprofen. Steroid injections may be used to prevent flares from recurring. Other options may include cognitive behavioral therapy, physical therapy, or acupuncture. In MS, the first line of treatment tends to be different from MS diagnosis to diagnosis.\n

Does mavenclad® improve quality of life for those with multiple sclerosis?

Mavenclad® significantly reduced most of the Quality of Life Questionnaire subscale score parameters in a cohort of patients with multiple sclerosis, with no significant difference in quality of life parameters when comparing before and after administration of Mavenclad®.

Who should consider clinical trials for multiple sclerosis?

Few patients with MS are interested in clinical trials and the willingness to undertake treatment in this setting is higher when treating other conditions: for this reason, our results could be biased by selection bias.

What are the common side effects of mavenclad®?

The side effects of mavenclad® are mainly injection site reactions like local pruritus and pain or inflammation at the injection site, fatigue, a burning cough, headaches, dizziness, nausea, vomiting, fever, muscle pains, shortness of breath, difficulty in breathing, and vomiting. Side effects can generally be avoided by administering the correct dose in the right setting and by staying on time, as the injection of VAREN will always be the same once the auto self injection takes effect - once in the arm.

How does mavenclad® work?

A formulation that delivers the biologically active moiety to the cells, when taken daily, can lead to a clinically significant reduction in MS Disease Activity Expanded (SPEL, or Seddon Score, or MRI Remission). This finding has been confirmed in other placebo-controlled, Phase I clinical trials. The most plausible mechanism of action may be through the inhibition of NF-κB mediated nuclear translocation, and down regulation of genes related with inflammation, like VCAM-1"

"Conus ritchiei\n\nConus ritchiei is an extinct species of sea snail, a marine gastropod mollusk in the family Conidae, the cone snails and their allies.

What is the latest research for multiple sclerosis?

All of the studies reported are still preliminary, but the results of this paper support a better understanding of the pathogenesis of MS lesions. The use of microRNAs is now an active area of research for all neurologic disorders, including MS. The role of these small molecules, in neuronal signalling, has also recently been tested in MS. Although more studies are needed, the current evidence suggests that miRNAs may be effective in controlling the progression of MS and that their pharmacological modulation may be a promising strategy for MS treatment in the near future.

Has mavenclad® proven to be more effective than a placebo?

A 6-week placebo-controlled trial in 40 patients with moderate to severe relapsing remitting multiple sclerosis assessed that Mavenclad® was significantly more effective than a placebo for improving the severity of relapsing-remitting disease activity\n\nThe US FDA had originally approved Apotransfusion's intravenous form of Ampyra, but Apotransfusion voluntarily halted further marketing of Ampyra in the US market. The FDA later approved Ampyra as an autoinfusion under a different brand name (Ampyra) and approved an intranasal formulation of Ampyra the following year.